At CPDC we are working with our partners to discover, develop and distribute the next generation of imaging agents and targeted radiotherapeutics for the detection and treatment of human diseases.
The role of radiopharmaceuticals in health care may still be quite a mystery for many Canadians, but this area has a tremendous therapeutic and commercial potential in our country. Canada is already a global leader in radioisotope-based health care technologies, meaning it has the strengths to also become a world leader in bringing related novel
Radiopharmaceuticals are a special class of drugs. They’re sometimes called molecular imaging probes, contrast agents, tracers or radiotherapeutics.
Radiopharmaceuticals contain a radioactive isotope and they are used to both diagnose and treat disease. Millions of patients receive radiopharmaceuticals annually for a wide variety of medical procedures ranging from the assessment of cardiac function to staging and treatment of cancer.
Hamilton, Ontario (October 22, 2020) ‐ Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the Company’s Board of Directors has appointed Bruno Paquin as Interim Chief Executive Officer, effective November 2, 2020. Justyna Kelly, CPDC’s outgoing CEO said, “Since joining CPDC,
CPDC is always looking for exceptional people to strengthen our team.
